BLACK DIAMOND THERAPEUTICS, INC. Payments to Acquire Investments
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Payments to Acquire Investments of $18.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2026-06-30 was $18.12M, a 79.81% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2025-12-31 was $35.90M, a 1101.17% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. payments to acquire investments for the quarter ending 2025-09-30 was $14.91M, a 46.47% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. payments to acquire investments for fiscal 2025 was $164.03M, a 33.49% increase from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. payments to acquire investments for fiscal 2024 was $122.88M, a 98.55% increase from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. payments to acquire investments for fiscal 2023 was $61.89M, a 2.90% increase from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. payments to acquire investments for fiscal 2022 was $60.14M, a 21.48% increase from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $18.12M 10-Q · filed 2026-08-05 | $54.03M derived: sum of 3 quarters · filed 2026-08-05 | $68.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $35.90M derived: sum of 2 quarters · filed 2026-05-07 | $50.81M derived: sum of 3 quarters · filed 2026-05-07 | $140.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $35.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $50.81M derived: sum of 2 quarters · filed 2026-03-16 | $140.56M derived: sum of 3 quarters · filed 2026-08-05 | $164.03M 10-K · filed 2026-03-16 |
| 2025-09-30 | $14.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $104.66M derived: sum of 2 quarters · filed 2026-08-05 | $128.12M 10-Q · filed 2025-11-06 | $131.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $89.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $113.21M 10-Q · filed 2026-08-05 | $116.20M derived: sum of 3 quarters · filed 2026-08-05 | $144.06M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $23.47M 10-Q · filed 2026-05-07 | $26.45M derived: sum of 2 quarters · filed 2026-05-07 | $54.31M derived: sum of 3 quarters · filed 2026-05-07 | $94.11M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $30.84M derived: sum of 2 quarters · filed 2026-03-16 | $70.64M derived: sum of 3 quarters · filed 2026-03-16 | $122.88M 10-K · filed 2026-03-16 |
| 2024-09-30 | $27.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $67.65M derived: sum of 2 quarters · filed 2025-11-06 | $119.89M 10-Q · filed 2025-11-06 | $135.67M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $39.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $92.03M 10-Q · filed 2025-08-07 | $107.82M derived: sum of 3 quarters · filed 2025-08-07 | $153.92M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $52.23M 10-Q · filed 2025-05-12 | $68.02M derived: sum of 2 quarters · filed 2025-05-12 | $114.12M derived: sum of 3 quarters · filed 2025-05-12 | $114.12M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $15.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $61.89M derived: sum of 2 quarters · filed 2025-03-06 | $61.89M derived: sum of 3 quarters · filed 2025-03-06 | $61.89M 10-K · filed 2025-03-06 |
| 2023-09-30 | $46.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $46.10M derived: sum of 2 quarters · filed 2024-11-05 | $46.10M 10-Q · filed 2024-11-05 | $69.79M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $23.69M derived: sum of 3 quarters · filed 2024-08-06 | $39.64M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $23.69M derived: sum of 2 quarters · filed 2024-05-09 | $39.64M derived: sum of 3 quarters · filed 2024-05-09 | $39.64M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $23.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $39.64M derived: sum of 2 quarters · filed 2024-03-12 | $39.64M derived: sum of 3 quarters · filed 2024-03-12 | $60.14M 10-K · filed 2024-03-12 |
| 2022-09-30 | $15.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $15.95M derived: sum of 2 quarters · filed 2023-11-06 | $36.45M 10-Q · filed 2023-11-06 | $41.38M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $20.50M 10-Q · filed 2023-08-11 | $25.43M derived: sum of 3 quarters · filed 2023-08-11 | $27.44M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $20.50M 10-Q · filed 2023-05-09 | $25.43M derived: sum of 2 quarters · filed 2023-05-09 | $27.44M derived: sum of 3 quarters · filed 2023-05-09 | $28.49M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $6.93M derived: sum of 2 quarters · filed 2023-03-09 | $7.98M derived: sum of 3 quarters · filed 2023-03-09 | $49.51M 10-K · filed 2023-03-09 |
| 2021-09-30 | $2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $3.06M derived: sum of 2 quarters · filed 2022-11-08 | $44.58M 10-Q · filed 2022-11-08 | $124.28M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $42.58M 10-Q · filed 2022-08-09 | $122.28M derived: sum of 3 quarters · filed 2022-08-09 | $135.44M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $41.53M 10-Q · filed 2022-05-11 | $121.23M derived: sum of 2 quarters · filed 2022-05-11 | $134.39M derived: sum of 3 quarters · filed 2022-05-11 | $414.00M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $79.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $92.86M derived: sum of 2 quarters · filed 2022-03-17 | $372.48M derived: sum of 3 quarters · filed 2022-03-17 | $372.48M 10-K · filed 2022-03-17 |
| 2020-09-30 | $13.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $292.77M derived: sum of 2 quarters · filed 2021-11-08 | $292.77M 10-Q · filed 2021-11-08 | $292.77M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $279.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $279.62M 10-Q · filed 2021-08-12 | $279.62M derived: sum of 3 quarters · filed 2021-08-12 | $279.62M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | $0.00 derived: sum of 2 quarters · filed 2021-05-07 | $0.00 derived: sum of 3 quarters · filed 2021-05-07 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 10-K · filed 2021-03-25 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $0.00 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |